Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213-2595, USA.
J Autism Dev Disord. 1995 Jun;25(3):283-94. doi: 10.1007/BF02179289.
The use of psychostimulants in autistic disorder has not received extensive evaluation. Furthermore, their use for the symptomatic control of autistic disorder has been felt to be contraindicated. This study investigates the use of methylphenidate (MPH) for the treatment of selected symptoms of autistic disorder. Ten children, ages 7-11, with a DSM-III-R diagnosis of autistic disorder participated in a double-blind crossover study using placebo and two MPH doses (10 mg or 20 mg bid). Subjects showed modest but statistically significant improvement on MPH over placebo. No significant side effects including worsening stereotypic movements occurred on either dose. Improvement in hyperactivity and lack of adverse effects suggest that MPH may be useful in the treatment of hyperactive autistic children.
在孤独症谱系障碍中使用精神兴奋剂尚未得到广泛评估。此外，人们认为将其用于孤独症谱系障碍的症状控制是禁忌的。本研究调查了哌甲酯（MPH）用于治疗孤独症谱系障碍特定症状的情况。10名年龄在7至11岁、根据《精神疾病诊断与统计手册第三版修订版》（DSM-III-R）诊断为孤独症谱系障碍的儿童参与了一项双盲交叉研究，使用安慰剂和两种MPH剂量（每日两次，每次10毫克或20毫克）。与安慰剂相比，受试者在MPH治疗下有适度但具有统计学意义的改善。两种剂量均未出现包括刻板动作恶化在内的显著副作用。多动症状的改善以及无不良反应表明，MPH可能对治疗多动的孤独症儿童有用。
